Program
Dupilumab coformulated with berahyaluronidase alfa
Its studies are mostly in Dermatitis, Atopic, led by Sanofi.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 11 open or running | phase 3since Oct 30, 2026 | Oct 30, 2026 | May 2, 2028phase 3 · NCT07919899 |
Also a collaborator on its studies: Regeneron Pharmaceuticals.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2026First study: phase 3 study in Dermatitis, AtopicFirst studyNCT07919899 · 150 planned
Ahead
- May 2, 2028Primary completion: phase 3 study in Dermatitis, AtopicNCT07919899
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07919899Dermatitis, Atopic | 3 | Not yet recruiting | May 2, 2028 | 150 |
How it is read
Names in the registry
- “Dupilumab coformulated with berahyaluronidase alfa”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.